BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate
Xinjian Huang, Dongni Shi, Xuxiazi Zou, Xuxia Wu, Shu‐Mei Huang, Lingzhi Kong, Muwen Yang, Yunyun Xiao, Boyu Chen, Xiangfu Chen, Ying Ouyang, Libing Song, Yunting Jian, Chuyong Lin
Abstract
Rationale: Chemoresistance is a major challenge in the clinical management of patients with breast cancer. Mutant p53 proteins tend to form aggregates that promote tumorigenesis in cancers. We here aimed to explore the mechanism for the generation of mutant p53 aggregates in breast cancer and assess its role in inducing chemoresistance. Methods: Expression of BCL2-associated athanogene 2 (BAG2) was evaluated by qRT-PCR, western blotting, and immunohistochemistry in breast cancer patient specimens. The significance of BAG2 expression in prognosis was assessed by Kaplan-Meier survival analysis and the Cox regression model. The roles of BAG2 in facilitating the formation of mutant p53 aggregates were analyzed by co-immunoprecipitation, immunofluorescence, and semi-denaturing detergent-agarose gel electrophoresis assays. The effects of BAG2 on the chemoresistance of breast cancer were demonstrated by cell function assays and mice tumor models.